Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Files An 8-K Financial Statements and Exhibits
Item9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit shall be deemed to be furnished, and not
filed:
| 99.1 |
RhopressaTM (netarsudil ophthalmic solution) 0.02% Rocket 4 Phase 3 6-Month Topline Results. |
About Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan. Its product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Rhopressa is a once-daily eye drop and a triple-action netarsudil ophthalmic solution. The active ingredient in Rhopressa acts through the inhibition of both Rho Kinase (ROCK) and norepinephrine transporter (NET). Roclatan is a once-daily, quadruple-action product candidate and is a fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with glaucoma. The Company is engaged in conducting Phase III clinical trials for Rhopressa and Roclatan. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Recent Trading Information
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) closed its last trading session down -0.60 at 42.55 with 361,591 shares trading hands.